
Pink Dx is an early-stage biotechnology company focused on improving women's health by developing innovative diagnostic solutions for gynecological cancers. The company aims to address the significant delays and invasiveness associated with current diagnostic procedures by utilizing advanced scientific methods, including bioinformatics and machine learning, to create tests that provide timely and accurate results. With a commitment to tackling unmet medical needs unique to women, Pink Dx is positioned to make a positive impact on healthcare outcomes for millions of women.

Pink Dx is an early-stage biotechnology company focused on improving women's health by developing innovative diagnostic solutions for gynecological cancers. The company aims to address the significant delays and invasiveness associated with current diagnostic procedures by utilizing advanced scientific methods, including bioinformatics and machine learning, to create tests that provide timely and accurate results. With a commitment to tackling unmet medical needs unique to women, Pink Dx is positioned to make a positive impact on healthcare outcomes for millions of women.
Stage & Funding: Series A — $45,000,000 total (initial $40M; $5M second close)
Focus: Early-stage women's health diagnostics, initial focus on gynecological cancers
Approach: Build clinical cohorts and apply bioinformatics & machine learning to develop non‑invasive tests
Headquarters: Daly City, California (USA)
Leadership: Bonnie Anderson (Co‑founder, CEO & Chair); Giulia Kennedy, Ph.D. (Co‑founder, CSO); Tim McMeekan (Co‑founder, CFO)
Women's health diagnostics (initial focus: gynecological cancers and unclear symptom presentations such as bloating, pelvic pain, abnormal bleeding).
2022
Biotechnology
$40,000,000
Initial announced Series A at public launch.
$5,000,000
Second close added new investors including Blue Venture Fund, Sandbox Clinical Ventures, and BEVC; brings reported total in the upsized Series A to $45,000,000.
“Backed by venture and strategic healthcare investors including Catalio Capital Management, The Production Board, Mountain Group Partners, Byers Capital, Mayo Clinic, Blue Venture Fund, Sandbox Clinical Ventures, and BEVC.”